2'-deoxy-2'-fluoroguanosine-3'-phosphate | 80681-28-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 核糖核苷3'-磷酸盐
• 英文名称: 2'-deoxy-2'-fluoroguanosine-3'-phosphate
• 英文别名: Gua-Ribf2F-P；[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate
• CAS: 80681-28-3
• 化学式: C₁₀H₁₃FN₅O₇P
• 分子量: 365.215
• InChiKey: JFQIKDMRHNEWOF-DXTOWSMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  182
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  在 ammonium hydroxide 、 溶剂黄146 作用下， 反应 3.0h， 生成 2'-deoxy-2'-fluoroguanosine-3'-phosphate
  参考文献：
  名称：

  Ikehara, Morio; Imura, Junko, Chemical and pharmaceutical bulletin, 1981, vol. 29, # 9, p. 2408 - 2412

  摘要：

  DOI：

文献信息

• Compositions and methods for inhibiting expression of the ALAS1 gene
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US10119143B2

  公开（公告）日：2018-11-06

  The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.

  本发明涉及靶向 ALAS1 基因的双链核糖核酸（dsRNA）组合物，以及使用这种 dsRNA 组合物改变（如抑制）ALAS1 表达的方法。
• COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：EP3052628B1

  公开（公告）日：2020-02-26
• [EN] DOSING OF SIRNA COMPOUNDS TO THE CISTERNA MAGNA<br/>[FR] DOSAGE DE COMPOSÉS D'ARNSI PAR RAPPORT À LA CISTERNA MAGNA
  申请人：[en]ALNYLAM PHARMACEUTICALS, INC.

  公开号：WO2022187617A1

  公开（公告）日：2022-09-09

  One aspect of the present invention relates to a double stranded iRNA agent comprising an antisense strand which is complementary to a target gene and one or more lipophilic moieties conjugated to one or more internal positions on at least one strand, which provides for targeting to, and uptake by, tissues and cells of the CNS via administration to a subarachnoid space,e.g., the cisterna magna. Another aspect of the invention relates to a method of gene silencing in tissues and cells of the CNS, that includes administering to the subarachnoid space of a subject in need thereof a therapeutically effective amount of the lipophilic moieties-conjugated double-stranded iRNAs.